Clinical Trials Logo
  1. Home
  2. Postherpetic Neuralgia
  3. NCT00168441
  4. Details
NCT00168441 Clinical Trial

A Study Evaluating Botulinum Toxin Type A in Subjects With Postherpetic Neuralgia

Postherpetic Neuralgia Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00168441
Other study ID # 191622-066
Secondary ID
Status Completed
Phase Phase 2
First received September 12, 2005
Last updated May 27, 2011
Start date June 2004
Est. completion date June 2005

Study information
Verified date May 2011
Source Allergan
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

4-month study including a 30-day baseline phase

Recruitment information / eligibility
Status Completed
Enrollment 117
Est. completion date June 2005
Est. primary completion date June 2005
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Postherpetic neuralgia for more than 3 months after the healing of a herpes zoster skin rash.

Exclusion Criteria:

- Previous use of botulinum toxin of any serotype or immunization to any botulinum toxin serotype.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• Botulinum Toxin Type A

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Allergan

Outcome
Type Measure Description Time frame Safety issue
Primary Pain score
Secondary Various Quality of Life questionnaires
Secondary Reduction in area of pain/allodynia
See also
  Status Clinical Trial Phase
Completed NCT04546334 - Erector Spinae Plane Block in Post-herpetic Neuralgia N/A
Completed NCT01688947 - Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN) Phase 2
Terminated NCT01744522 - Leech Therapy for Postherpetic Neuralgia N/A
Completed NCT00478179 - Study of a Bupivacaine Patch (Eladur™) to Treat Post- Herpetic Neuralgia Phase 2
Completed NCT00566904 - New Topical Treatment for Continued Pain After Shingles Phase 1
Completed NCT04099706 - Treatment of Chronic Postherpetic Pain With Autologous Fat Grafting - A RCT N/A
Terminated NCT01603394 - Pilot Study Of Pregabalin And Prediction Of Treatment Response In Patients With Postherpetic Neuralgia Phase 4
Completed NCT01228838 - Study of NGX-1998 for the Treatment of Postherpetic Neuralgia Phase 2
Completed NCT01251211 - Botulinum Toxin in Peripheral Neuropathic Pain Phase 4
Completed NCT00612105 - Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN) Phase 2
Recruiting NCT04560361 - The Analgesic Effect of Electroacupuncture on Postherpetic Neuralgia N/A
Recruiting NCT05568186 - Correlation Between Thermal Patterns of Infrared Thermal Imaging and Clinical Phenotype in Patients With Postherpetic Neuralgia
Recruiting NCT04664530 - The Study on the Esketamine in the Treatment of Postherpetic Neuralgia Phase 4
Active, not recruiting NCT01508676 - Effects of Pennsaid on Clinical Neuropathic Pain N/A
Completed NCT00885586 - Acupuncture in Herpes Zoster Neuralgia (ACUZoster) Phase 4
Completed NCT00981227 - Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Post-Herpetic Neuralgia Phase 2
Completed NCT00576108 - A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN) Phase 2
Completed NCT00238511 - An Open-Label Follow-on Trial to Assess the Long-Term Safety and Efficacy of Oral SPM 927 in Subjects With Postherpetic Neuralgia (PHN) Phase 2
Completed NCT00007501 - Shingles Prevention Study Phase 3
Completed NCT04594226 - Electroacupuncture Therapy for Treating Postherpetic Neuralgia N/A